Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of John L. Nitiss

John L. Nitiss


Professor of Pharmacology, College of Pharmacy - Pharmaceutical Sciences
Associate Head for Research, College of Pharmacy - Pharmaceutical Sciences
Assistant Dean for Research, Rockford Campus, College of Pharmacy
Adjunct professor, College of Medicine - Medical Biotechnology

Contact

Address:

1601 Parkview Avenue, Rockford, IL

Office Phone:

(815) 395-5583 (work)

Related Sites:

About Heading link

Research Interests:
Mechanisms of action of anticancer drugs; DNA topoisomerases and their roles in biological processes; microbial model systems of drug action; biochemistry and biology of non-homologous recombination; repair inhibitors and cancer chemotherapy.

Teaching and Supervision Heading link

Principles and techniques of Molecular Biology (MBT 505), 8/23/2021 – 12/3/2021
Colloquium Lecture Series (PSCI 425), 8/23/2021 – 12/3/2021
Colloquium Lecture Series (PSCI 425), 8/23/2021 – 12/3/2021
PDAT 9:Hematology/Oncology (Phar 509), 1/11/2021 – 5/7/2021
Spec Topics Biopharm Sci (BPS 594), 1/11/2021 – 4/30/2021
Colloquium for PharmDs (BPS 425), 8/24/2020 – 12/4/2020
Molecular Biology, 8/24/2020 – 12/4/2020
Colloquium for PharmDs (BPS 425), 8/24/2020 – 12/4/2020
Biopharmaceutical Sci II (BPS 502), 1/13/2020 – 5/1/2020

Selected Grants

Genome Instability induced in cancer cells carrying mutations in Type II topoisomerases, National Institutes of Health (National Cancer Institute)., 12/20/2021 - 11/30/2023, Obligated Amount: $79950; Anticipated Amount: $159900

DNA Topoisomerase Misfunctioning in Neurological Disease, National Institutes of Health (National Institute of Neurological Disorders and Stroke)., 1/1/2021 - 11/30/2022, Obligated Amount: $159900; Anticipated Amount: $159900

Novel Approaches for Studying Topoisomerase 2 Targeting Anti-Cancer Drugs, National Institutes of Health (National Cancer Institute)., 4/1/2017 - 3/31/2020, Obligated Amount: $159900; Anticipated Amount: $159900

Regulation of Non-Homologous End Joining Through End Processing, National Institutes of Health (National Cancer Institute)., 7/1/2014 - 12/31/2017, Obligated Amount: $360967; Anticipated Amount: $360967

DNA Repair And Antitopoisomerase Drug Effects, National Institutes of Health (National Cancer Institute)., 9/2/2011 - 7/31/2012, Obligated Amount: $5953; Anticipated Amount: $5953

Anti-Topoisomerase Drug Action in Yeast, National Institutes of Health (National Cancer Institute)., 9/2/2011 - 1/31/2016, Obligated Amount: $982606; Anticipated Amount: $1008094

Studies of Childhood Solid Tumors, National Cancer Institute., 8/1/1978 - 7/31/2013, Obligated Amount: $43592000; No Anticipated Amount Set

Selected Publications

Sun, Yilun, Nitiss, John L, Pommier, Yves. (2022). SUMO: A Swiss Army Knife for Eukaryotic Topoisomerases. Frontiers in Molecular Biosciences, 9, 871161. doi:10.3389/fmolb.2022.871161.

Menendez, Daniel, Anand, Jay R, Murphy, Carri C, Bell, Whitney J, Fu, Jiaqi, Slepushkina, Nadia, Buehler, Eugen, Martin, Scott E, Lal-Nag, Madhu, Nitiss, John L, Resnick, Michael A. (2022). Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity. Oncotarget, 13, (1), 332-346. doi:10.18632/oncotarget.28195.

Boot, Arnoud, Liu, Mo, Stantial, Nicole, Shah, Viraj, Yu, Willie, Nitiss, Karin C, Nitiss, John L, Jinks-Robertson, Sue, Rozen, Steven G. (2022). Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers. Proceedings of the National Academy of Sciences of the United States of America, 119, (4), e2114024119. doi:10.1073/pnas.2114024119.

Nitiss, John L, Kiianitsa, Kostantin, Sun, Yilun, Nitiss, Karin C, Maizels, Nancy. (2021). Topoisomerase Assays. Current Protocols, 1, (10), e250. doi:10.1002/cpz1.250.

Sun, Yilun, Miller Jenkins, Lisa M, Su, Yijun P, Nitiss, Karin C, Nitiss, John L, Pommier, Yves. (2020). A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation. Science Advances, 6, (46), eaba6290. doi:10.1126/sciadv.aba6290.

Stantial, Nicole, Rogojina, Anna, Gilbertson, Matthew, Sun, Yilun, Miles, Hannah, Shaltz, Samantha, Berger, James, Nitiss, Karin C, Jinks-Robertson, Sue, Nitiss, John L. (2020). Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast. Proceedings of the National Academy of Sciences of the United States of America, 117, (43), 26876-26884. doi:10.1073/pnas.2008721117.

Wang, Yunke, Rakela, Samantha, Chambers, Jeremy W, Hua, Zi-Chun, Muller, Mark T, Nitiss, John L, Tse-Dinh, Yuk-Ching, Leng, Fenfei. (2019). Kinetic Study of DNA Topoisomerases by Supercoiling-Dependent Fluorescence Quenching. ACS Omega, 4, (19), 18413-18422. doi:10.1021/acsomega.9b02676.

Nitiss, Karin C, Nitiss, John L, Hanakahi, Leslyn A. (2019). DNA Damage by an essential enzyme: A delicate balance act on the tightrope. DNA Repair, 82, 102639. doi:10.1016/j.dnarep.2019.102639.

Blower, Tim R, Bandak, Afif, Lee, Amy SY, Austin, Caroline A, Nitiss, John L, Berger, James M. (2019). A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents. Nucleic Acids Research, 47, (15), 8163-8179. doi:10.1093/nar/gkz579.

Education

Degrees:
Ph.D., Illinois Institute of Technology, United States, 1986
S.B., University of Chicago, United States, 1978

Postgraduate Training:
Post-doctoral fellow, Harvard University, United States, 1989